The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.
 
Michael J. Guarino
No Relationships to Disclose
 
Alexander Starodub
Honoraria - Immunomedics
 
Gregory A. Masters
No Relationships to Disclose
 
Rebecca Suk Heist
No Relationships to Disclose
 
Wells A. Messersmith
Consulting or Advisory Role - Morphotek; OncoMed
Research Funding - GlaxoSmithKline; Immunomedics; Millennium; OncoMed; Pfizer; Roche; Roche/Genentech
 
Aditya Bardia
No Relationships to Disclose
 
Allyson J. Ocean
Honoraria - Immunomedics
 
Sajeve Samuel Thomas
No Relationships to Disclose
 
Pius P Maliakal
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
William A. Wegener
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
Robert M. Sharkey
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
Francois Wilhelm
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
David M. Goldenberg
Employment - Immunomedics
Leadership - Immunomedics
Stock and Other Ownership Interests - Immunomedics
Patents, Royalties, Other Intellectual Property - Immunomedics
Travel, Accommodations, Expenses - Immunomedics